Company / Capital Expenditures
United Therapeutics Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$520.5M
FY2025
5-year range
$120.8M / $520.5M
FY2021-FY2025
Trend
+111.2%
vs FY2024
Sector context
#10 of 194
Health Care
What the data says
Among 194 Health Care companies, United Therapeutics is in the top 5% for capital expenditures. Capital Expenditures has increased for 5 consecutive years, from $59M in FY2020 to $521M in FY2025.
Based on SEC 10-K filings.
$521M in FY2025 with a 5-year CAGR of +54.4%. Top quartile in the Health Care sector.
Improved from $230M to $521M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +55.4%
- 5-Year CAGR
- +54.4%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 194This company $520.5M Sector average $117.5M
▼
+342.9% above sector average
Key checks
Key Insights
- United Therapeutics's capital expenditures has grown for 5 consecutive years.
- 5-year CAGR of +54.4%, indicating consistent growth.
- In FY2025, capital expenditures increased 111.2% year-over-year.
- Ranks #10 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $520.5M | +111.2% |
| FY2024 | $246.5M | +7.0% |
| FY2023 | $230.4M | +66.0% |
| FY2022 | $138.8M | +14.9% |
| FY2021 | $120.8M | +103.7% |
| FY2020 | $59.3M | -29.2% |
| FY2019 | $83.7M | -54.6% |
| FY2018 | $184.4M | +270.3% |
| FY2017 | $49.8M | +31.1% |
| FY2016 | $38.0M | -23.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026